Status In progress
Process STA
ID number 970

Provisional Schedule

Committee meeting: 3 12 December 2017

Project Team

Project lead Stephanie Yates

Email enquiries

Consultees

Companies sponsors Roche Products (atezolizumab)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (docetaxel) (not participating, confidentiality agreement not signed)
  Actavis UK (pemetrexed, docetaxel) (not participating, confidentiality agreement not signed)
  Boehringer Ingelheim (nintedanib)
  Bristol Myers Squibb (nivolumab) (not participating, confidentiality agreement not signed)
  Dr Reddy’s Laboratories (docetaxel) (not participating, confidentiality agreement not signed)
  Hospira UK (docetaxel) (not participating, confidentiality agreement not signed)
  Medac GmbH (docetaxel) (not participating, confidentiality agreement not signed)
  Merck Sharp & Dohme (pembrolizumab)
  Sanofi (docetaxel) (not participating, confidentiality agreement not signed)
  Seacross Pharmaceuticals (docetaxel) (not participating, confidentiality agreement not signed)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Cancer Research Institute

Timeline

Key events during the development of the guidance:

Date Update
03 November 2017 Following the second ACD consultation the committee meeting scheduled for 9 November 2017 has been cancelled. This is to allow the company (Roche) additional time to submit new evidence and NICE adequate time to review the evidence prior to consideration by the appraisal committee.
11 October 2017 - 01 November 2017 Appraisal consultation: 2
13 September 2017 Committee meeting: 2
03 August 2017 - 24 August 2017 Appraisal consultation
14 June 2017 Committee meeting: 1
08 December 2016 Invitation to participate
08 June 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance